Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666615 | 0.88 | ALDH1A1 (0.43) | TRPV1SMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL3665420 | 0.81 | TRPV1 (0.53) | TRPV1SMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL3666624 | 0.81 | TGM2 (0.57) | SMN1; SMN2TP53ALDH1A1MEN1NPC1 | |
| SCHEMBL3699355 | 0.80 | TSHR (0.39) | TP53ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL3635282 | 0.79 | GAA (0.46) | TRPV1ALDH1A1MEN1LMNAGAA | |
| SCHEMBL3667723 | 0.79 | PEPD (0.47) | SMN1; SMN2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL3632504 | 0.76 | KDM4E (0.41) | TP53ALDH1A1KDM4EMAPT | |
| SCHEMBL3665310 | 0.76 | GAA (0.41) | SMN1; SMN2ALDH1A1MEN1NPC1GAA | |
| SCHEMBL5692466 | 0.75 | SMN1; SMN2 (0.57) | TRPV1SMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL3665667 | 0.74 | TRPV1 (0.51) | TRPV1ALDH1A1MEN1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | claimed |
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | claimed |
| EP-2131854-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | Aeterna Zentaris Gmbh (DE) | 2009-12-16 | — | — | EP | claimed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | claimed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | claimed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | claimed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2131854-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | Aeterna Zentaris Gmbh (DE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | TRPV1 125/4885SMN1; SMN2 4297/4885TP53 4832/4885 |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | LHCGR, GNRHR, FSHR | TRPV1 857/4885SMN1; SMN2 3061/4885TP53 3190/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | TRPV1 125/4885SMN1; SMN2 4297/4885TP53 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.